Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2024-02-12 , DOI: 10.1080/14737167.2024.2310684
Jorge Mestre-Ferrandiz ₁ , Marcin Czech ₂ , Josef S. Smolen ₃ , Paul Cornes ₄ , Matti S. Aapro ₅ , Silvio Danese ₆ , Stephen Deitch ₇ , Hannah Tyldsley ₇ , Will Foster ₇ , Pooja Shah ₈ , Mark Latymer ₉ , Arnold G. Vulto ₁₀

Affiliation

Biosimilars have improved access to biologic medicines; however, historical thinking may jeopardize the viability of future markets.An expert panel of eight diverse European stakeholders provided i...

中文翻译：